Northwestern Medicine

Latest Content

Closing the Diagnostic, Monitoring Gap for IgG4-RD, With Robert Woodrick, MD

ByRobert Woodrick, MD

August 13th 2026

Woodrick discusses how his team monitors subclinical progression and the multidisciplinary consortium supporting care.

Eric Ruderman, MD: 20 Years of Combined Psoriatic Derm-Rheum Care

ByEric M. Ruderman, MD

August 11th 2026

Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.

How Ready is CAR-T for Systemic Sclerosis: Carrie Richardson, MD

ByCarrie Richardson, MD

August 3rd 2026

Richardson discusses the safety profile of CD19 CAR-T, the debate over B cell targets, and more.

CAR-T's Early Promise for Reversing Damage in Systemic Sclerosis

ByCarrie Richardson, MD

July 31st 2026

Carrie Richardson, MD, discusses what early CAR-T trial data mean for reversing damage and redefining remission in systemic sclerosis.

Slow But Steady: Real-World Data Supports Avacopan Use in GPA/MPA

ByAnisha B. Dua, MD, MPH

June 4th 2026

Anisha Dua, MD, MPH, discusses the largest US real-world cohort to date in GPA/MPA.

Entering A New Era of Steroid-Sparing Options for Polymyalgia Rheumatica, With Anisha Dua, MD, MPH

ByAnisha B. Dua, MD, MPH

March 10th 2026

Dua discussed how management of PMR has continued to change over the past couple of years.

Improving Recognition and Outcomes in Vasculitis, with Anisha Dua, MD

ByAnisha B. Dua, MD, MPH

February 19th 2026

Dua discussed the vasculitis field's progression to "precision medicine" and more.

GLP-1 RAs and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 18th 2026

Ruderman emphasized growing interest in metabolic health with the rise of GLP-1 RA usage.

Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD

ByAnisha B. Dua, MD, MPH

February 14th 2026

Dua discussed the latest guideline updates, the most recent since 1990.

Treatment Choices and Sequencing in PsA, With Eric Ruderman, MD

ByEric M. Ruderman, MD

February 13th 2026

Ruderman discussed recent research examining treatment choices after failure.

Improving Diagnostic Precision and Long-Term Control in Large Vessel Vasculitis, with Anisha Dua, MD, MPH

ByAnisha B. Dua, MD, MPH

February 12th 2026

Dua emphasized exciting progress in the field for giant cell and arteritis and Takeyasu arteritis.

Difficult-to-Treat Disease in PsA and axSpA: Lessons from 2025, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 11th 2026

Ruderman discussed the topics of his year in review talks at RWCS 2026.

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

January 13th 2026

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

Northwestern Medicine

Latest Content

Closing the Diagnostic, Monitoring Gap for IgG4-RD, With Robert Woodrick, MD

Eric Ruderman, MD: 20 Years of Combined Psoriatic Derm-Rheum Care

How Ready is CAR-T for Systemic Sclerosis: Carrie Richardson, MD

CAR-T's Early Promise for Reversing Damage in Systemic Sclerosis

Slow But Steady: Real-World Data Supports Avacopan Use in GPA/MPA

Entering A New Era of Steroid-Sparing Options for Polymyalgia Rheumatica, With Anisha Dua, MD, MPH

Improving Recognition and Outcomes in Vasculitis, with Anisha Dua, MD

GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD

Treatment Choices and Sequencing in PsA, With Eric Ruderman, MD

Improving Diagnostic Precision and Long-Term Control in Large Vessel Vasculitis, with Anisha Dua, MD, MPH

Difficult-to-Treat Disease in PsA and axSpA: Lessons from 2025, with Eric Ruderman, MD

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

Trending on Rheumatology Live

Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline

Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD

Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD

INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH

Selecting Sjögren’s Patients for Ianalumab and Weighing Safety